Copeland Capital Management LLC Sells 8,840 Shares of STERIS plc $STE

Copeland Capital Management LLC reduced its position in STERIS plc (NYSE:STE - Free Report) by 4.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 175,671 shares of the medical equipment provider's stock after selling 8,840 shares during the quarter. Copeland Capital Management LLC owned approximately 0.18% of STERIS worth $44,537,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Steigerwald Gordon & Koch Inc. bought a new position in shares of STERIS in the third quarter worth approximately $25,000. Board of the Pension Protection Fund bought a new position in shares of STERIS during the fourth quarter worth $25,000. Harbor Investment Advisory LLC boosted its position in shares of STERIS by 115.4% during the fourth quarter. Harbor Investment Advisory LLC now owns 112 shares of the medical equipment provider's stock worth $28,000 after acquiring an additional 60 shares during the last quarter. Cloud Capital Management LLC bought a new position in shares of STERIS during the third quarter worth $29,000. Finally, Geneos Wealth Management Inc. boosted its position in shares of STERIS by 416.0% during the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider's stock worth $29,000 after acquiring an additional 104 shares during the last quarter. 94.69% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

STE has been the subject of a number of research reports. Wall Street Zen upgraded shares of STERIS from a "buy" rating to a "strong-buy" rating in a research report on Saturday, April 18th. Weiss Ratings lowered shares of STERIS from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Thursday, April 16th. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $275.20.

STERIS Price Performance

STERIS stock opened at $223.37 on Friday. The company has a market cap of $21.91 billion, a price-to-earnings ratio of 31.15 and a beta of 1.07. The firm's fifty day moving average is $229.34 and its 200 day moving average is $245.43. The company has a quick ratio of 1.75, a current ratio of 2.48 and a debt-to-equity ratio of 0.26. STERIS plc has a 52-week low of $209.98 and a 52-week high of $269.44.

STERIS (NYSE:STE - Get Free Report) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. The company's revenue was up 9.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.32 EPS. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. Sell-side analysts forecast that STERIS plc will post 10.22 EPS for the current fiscal year.

STERIS Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 19th. Investors of record on Tuesday, February 17th were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Tuesday, February 17th. This represents a $2.52 dividend on an annualized basis and a yield of 1.1%. STERIS's dividend payout ratio is presently 35.15%.

Insider Transactions at STERIS

In related news, Director Cynthia L. Feldmann sold 3,098 shares of the company's stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $237.21, for a total transaction of $734,876.58. Following the sale, the director owned 705 shares of the company's stock, valued at $167,233.05. This represents a 81.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.07% of the stock is currently owned by insiders.

STERIS Profile

STERIS Corporation NYSE: STE is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.